MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Motor Phenotype Changes over time in Parkinson’s Disease. A 5-year Follow-up Study

    MF. Valero García, E. Bargay Pizarro, I. Legarda Ramirez, B. Vives Pastor, L. Núñez Santos, S. Jesus Maestre, M. Cosgaya, J. Garcia Caldentey, N. Caballol, J. Hernández Vara, I. Cabo, L. López Manzanares, I. González Aramburu, C. Borrué, B. Solano Vila, M. álvarez Saúco, L. Vela, S. Escalante, E. Cubo, JC. Martínez Castrillo, P. Sánchez Alonso, MG. Alonso Losada, N. López Ariztegui, I. Gastón, J. Kulisevsky, M. Seijo Martinez, C. Ordás, P. Martinez-Martin, P. Mir, D. Santos-García (Palma de Mallorca, Spain)

    Objective: The objectives of this study are to describe the prevalence of different motor phenotypes (MP) in a cohort of Parkinson’s Disease (PD) patients, to…
  • 2024 International Congress

    Developing a selection framework for digital measures of Parkinson’s disease progression for the EJS ACT-PD trial

    R. Ellis-Doyle, ML. Zeissler, C. Gonzalez-Robles, M. Bartlett, S. Collins, S. Del-Din, S. Haar, M. Hu, A. Jha, C. Lambert, A. Noyce, R. Petty, K. Pushparatnam, L. Rochester, C. Siu, G. Mills, A. Schrag, T. Foltynie, C. Carroll, A. Yarnall (London, United Kingdom)

    Objective: To develop a selection process for digital measures (DMs) to include as exploratory outcome measures of Parkinson’s disease (PD) progression in a platform disease…
  • 2024 International Congress

    Integrated Clinical Research Intern Program: Impact Upon Recruitment of Participants for Therapeutic Studies Aimed at Parkinson’s Disease (PD) Prevention.

    L. Lemon, A. Faraday, J. Nevins, M. Nygard, M. Mcmahon (Cincinnati, USA)

    Objective: To discuss the development and benefit of an online internship program created to expand recruitment and retention within a PD cohort and introduce students…
  • 2024 International Congress

    Improvement in Uninterrupted Good ON Time and Reduction in OFF Periods with CSAI Treatment

    D. Kremens, R. Hauser, A. Formella, M. Joshi, M. Grall (Philadelphia, USA)

    Objective: Evaluate the effect of continuous subcutaneous apomorphine infusion (CSAI) on daily periods of OFF time and Good ON time (ON without troublesome dyskinesia) in…
  • 2024 International Congress

    Neuroprotective Effect of Isoquercitrin in Rotenone Induced Parkinson’s Disease-Like Motor and non-motor Symptoms in Zebrafish

    KHA. Aran (Moga, India)

    Objective: The objective of study is to find out the effect of isoquercitrin, a plant-derived chemical, against Parkinson-like symptoms induced by rotenone in zebrafish.. Background:…
  • 2024 International Congress

    Validating the clinical stage NLRP3 inflammasome inhibitor nibrozetone as a disease-modifying therapeutic for Parkinson’s disease

    R. Gordon, K. Bhatt, N. Jayabalan, N. Birch, A. Lehn, B. Oronsky, S. Caroen, T. Reid (Brisbane, Australia)

    Objective: We recently confirmed that nibrozetone (RRx-001), a Phase 3 small molecule chemoprotective agent, is a direct NLRP3 inhibitor that is CNS permeable. Nibrozetone displays…
  • 2024 International Congress

    Continuous Dopaminergic Stimulation-based Levodopa Treatment in Early to Mid-stage Parkinson’s Disease Patients: A Systematic Review and Meta-analysis

    R. Tang, R. Sun, S. Zhang, L. Chen (Shanghai, China)

    Objective: To compare the clinical effectiveness between continuous dopaminergic stimulation (CDS)-based and intermittent levodopa (IL) treatment in patients with early to mid-stage Parkinson’s disease (PD).…
  • 2024 International Congress

    Comparing the Selected Device-Aided Therapy of Movement Disorder Specialist Team with Patient Selections

    A. de Leon, O. Phokeawvarangkul, R. Bhidayasiri (Bangkok, Thailand)

    Objective: This study aims to compare the decision made by patients and physicians in selecting device-aided therapy (DAT) for advanced Parkinson’s disease (aPD) and to…
  • 2024 International Congress

    Indications of advanced therapies in Parkinson’s Disease: a retrospective study in a Belgian reference center

    B. Delsaut, V. Leclercq, S. Dethy (La Louvière, Belgium)

    Objective: The aim of our study is to assess whether our patients with Parkinson’s disease (PD) met recommended criteria to perform advanced therapy (AT) like…
  • 2024 International Congress

    Effects of GBA mutations in patients with Parkinson’s disease and Levodopa-carbidopa intestinal gel: a nation-wide longitudinal multicentre ‘real-world’ study.

    R. Cilia, F. Colucci, E. Cereda, V. Leta, M. Zibetti, M. Carecchio, S. Bonvegna, G. Calandra-Buonaura, R. Cerroni, R. de Micco, S. Tamburin, L. Magistrelli, F. Lena, M. Mascia, M. Picillo, G. Cossu, M. Marano, C. Leuzzi, C. Comi, A. Zampogna, C. Pellicano, S. Barca, V. Fioravanti, A. Pilotto, R. Zangaglia, M. Avenali, C. Sorbera, F. Di Biasio, F. Arienti, A. Nicoletti, C. Bagella, MC. Malaguti, A. Ranghetti, E. Caputo, D. Alimonti, E. Torre, GD. Oggioni, AE. Elia, N. Golfrè Andreasi, G. Devigili, B. Garavaglia, G. Imbalzano, T. Schirinzi, F. Cavallieri, A. Priori, M. Sessa, F. Tamma, M. Canesi, P. Solla, M. Zappia, A. Di Fonzo, L. Avanzino, A. Quartarone, EM. Valente, C. Pacchetti, A. Padovani, F. Valzania, A. Suppa, MT. Pellecchia, N. Modugno, M. Tinazzi, A. Tessitore, A. Stefani, P. Cortelli, IU. Isaias, A. Antonini, MC. Sensi, L. Lopiano, R. Eleopra (Milan, Italy)

    Objective: To investigate the safety and efficacy of LCIG in PD, focusing on the effects of GBA status. Background: Parkinson's disease carriers of GBA mutations/variants…
  • « Previous Page
  • 1
  • …
  • 127
  • 128
  • 129
  • 130
  • 131
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley